Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have received an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $29.50.

ROIV has been the subject of a number of research analyst reports. The Goldman Sachs Group raised their target price on Roivant Sciences from $24.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Citigroup boosted their target price on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Finally, HC Wainwright increased their price target on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th.

Roivant Sciences Price Performance

ROIV stock opened at $27.70 on Friday. Roivant Sciences has a 1 year low of $8.73 and a 1 year high of $30.33. The firm has a 50-day moving average of $25.92 and a 200 day moving average of $21.19. The company has a market cap of $19.82 billion, a P/E ratio of -23.68 and a beta of 1.17.

Insiders Place Their Bets

In other Roivant Sciences news, insider Mayukh Sukhatme sold 339,441 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $26.47, for a total transaction of $8,985,003.27. Following the completion of the transaction, the insider owned 19,148,664 shares of the company’s stock, valued at approximately $506,865,136.08. This trade represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Melissa B. Epperly sold 41,861 shares of Roivant Sciences stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the transaction, the director owned 15,804 shares of the company’s stock, valued at $453,258.72. The trade was a 72.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 6,794,685 shares of company stock valued at $173,053,290. Insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently modified their holdings of the stock. SBI Securities Co. Ltd. increased its holdings in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after acquiring an additional 1,166 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after purchasing an additional 1,148 shares in the last quarter. Allworth Financial LP boosted its stake in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares in the last quarter. Bessemer Group Inc. grew its position in Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in Roivant Sciences during the 4th quarter valued at about $47,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.